Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Conditions

• Schizophrenia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Digital Therapeutic — DEVICE
  A prescription digital therapeutic in the form of a smartphone app.

Study Details

This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.

Key Dates

Start date

Mar 31, 2023

Status verified

Oct 2025

Primary completion

Jun 20, 2025

Completion

Jul 23, 2025

Study Design

Enrollment

464 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Digital Therapeutic A
  Evaluate the efficacy and safety of digital therapeutic A as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
• Experimental: Digital Therapeutic B
  Evaluate the efficacy and safety of digital therapeutic B as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.

Primary Outcome Measure

Experiential negative symptoms [ Time Frame: Baseline to Week 16 ]

Locations (54)

Find similar trials in Chandler, AZ

Related Studies

• Zyprexa® Relprevv™ Patient Care Program
  Enrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania
• Database Registry for Neural Network Biomarkers in Psychosis
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
• Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
  Recruiting · Yale University · New Haven, Connecticut
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
  PHASE4 · Recruiting · Corporal Michael J. Crescenz VA Medical Center · Philadelphia, Pennsylvania